Results from the Phase 3 VERITAC-2 trial show an investigational treatment reduces risk of disease progression in ESR1-mutant, ER+/HER2- advanced breast cancer.

Learn more about the data also published in The New England Journal of Medicine here.

Data from the pivotal Phase 3 BREAKWATER trial demonstrates combination regimen’s potential as new standard of care.

Read more about the findings also published in The New England Journal of Medicine.

Five-year follow-up data from the Phase 3 ARCHES trial showing a treatment combination reduces risk of death.

Learn more about the findings being presented at ASCO here.

More than 60 abstracts, including 15 oral and rapid oral presentations, highlight advancements across Pfizer’s industry-leading Oncology portfolio and pipeline.

Learn more about Pfizer’s presence at the conference here.

A world where people with cancer live better and longer lives—that’s Pfizer’s vision. Pfizer is accelerating breakthrough medicines that bring new hope to patients everywhere.

Learn more at Let’s Outdo Cancer.

Sign up to receive real-time updates on Pfizer’s news at ASCO from the Pfizer Media Relations team delivered directly to your inbox.